Side-by-side comparison of AI visibility scores, market position, and capabilities
Digital dental imaging and practice management software provider offering intraoral sensors, 3D imaging systems, and clinical software for dental practices and institutions worldwide.
Carestream Dental is a Rochester, New York-based provider of dental imaging technology and practice management software, operating as a business unit spun off from Carestream Health. The company offers a comprehensive portfolio of dental imaging solutions spanning intraoral X-ray sensors, panoramic imaging systems, 3D cone beam CT (CBCT) scanners, and the clinical software required to acquire, store, manage, and interpret dental images. Carestream Dental serves general dental practices, specialty clinics, dental schools, and group dental organizations globally.\n\nThe company's imaging software platforms, including CS Imaging and CS PracticeWorks, integrate clinical image management with practice workflow features such as patient scheduling, charting, and treatment planning. This integration between imaging hardware and software creates a vertically integrated ecosystem that encourages multi-product adoption within a single practice. Carestream Dental has built a significant installed base in North America and Europe over several decades of operation as part of larger parent organizations including Kodak and Carestream Health.\n\nCarestream Dental competes in the dental technology market against companies such as Dentsply Sirona, Planmeca, and Patterson Companies. The transition from film-based to digital radiography was a key growth driver historically, and the company now focuses on 3D imaging adoption, digital impression workflow integration, and cloud-connected imaging tools. Its deep roots in imaging hardware combined with proprietary software give it a bundled solution advantage when selling into practices upgrading their full radiography infrastructure.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.